Side by side
Cagrilintide vs Retatrutide
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Cagrilintide | Retatrutide | |
|---|---|---|
| What it is | A long-acting amylin analogue in late-stage trials. It works on a different satiety pathway from the GLP-1 drugs. Which is why it is being developed alongside semaglutide rather than against it. | An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere. |
| EvidenceHow much human evidence exists, not how well it works. | Clinical trials | Early human trials |
| Regulatory statusReviewed 2026-08-16 | Not approved anywhere, alone or in combination. In late-stage clinical development as CagriSema, a fixed combination with semaglutide. Anything sold as cagrilintide today is a research chemical produced outside the manufacturing controls that a future approval would rest on. | Investigational. Not approved for human use in any jurisdiction. Sold only as a research chemical, with no manufacturing standard behind that label. |
| Routes | Subcutaneous | Subcutaneous |
| Half-life | 180 hours | 144 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $4.40/mg | $1.25/mg |
| Median per mg | $9.60/mg | $5.17/mg |
| Vendors with a price | 31 | 37 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.